- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Corcept Therapeutics Incorporated (CORT)
The Corcept share price today is 122.25, view NASDAQ CORT stock exchange data. Track the latest Corcept share price with real-time updates on CORT stock performance including market cap, day range, 52-week range and dividend yield. Access CORT charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
120.56
123.44
52 wk Range
28.66
123.44
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
120.56123.44
52 wk Range
28.66123.44
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CORT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
141.00
Upside
+15.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 141.00
(+15.34% Upside)
Corcept Therapeutics Incorporated Earnings Call Summary for Q2/2026
- Q2 revenue surged 32% YoY to $256.1M, beating forecast by $37M; full-year guidance raised to $1.1B-$1.2B from prior range
- LIFYORLI generated $47.6M in debut quarter with 1,300+ patients enrolled; management called it one of strongest oncology launches ever
- Korlym franchise posted $208.6M revenue, up 27% sequentially, with record prescriptions and prescribers across Cushing's syndrome business
- Shares jumped 20.82% after-hours to $112.30, surpassing 52-week high; net income rose 23% to $43M with flat operating expenses
- Relacorilant PDUFA date set for Dec 17, 2026; company projects Cushing's business reaching $2B annually by decade-end
Last Updated: 30-07-2026, 03:14 am
Read Full TranscriptEarnings
Latest Release
29-07-2026
EPS / Forecast
0.36 / 0.01
Revenue / Forecast
256.1M / 217.85M
Compare CORT to Peers and Sector
Metrics to compare | CORT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCORTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 243.5x | 17.3x | −0.4x | |
PEG Ratio | −4.11 | −0.25 | 0.00 | |
Price/Book | 18.7x | 3.6x | 2.6x | |
Price / LTM Sales | 15.9x | 2.3x | 3.1x | |
Upside (Analyst Target) | 34.2% | 13.4% | 48.9% | |
Fair Value Upside | Unlock | 29.1% | 6.2% | Unlock |
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Corcept (CORT) Share Price Today?
The Corcept share price today is 122.25.
What is the current Corcept (CORT) share price and day range?
As of 23-08-2026, the Corcept share price is 122.25, with a previous close of 121.05. The share price has ranged from 120.56 to 123.44 today, while the 52-week range spans from 28.66 to 123.44.
What Is the Corcept Market Cap?
As of today, Corcept market cap is 13.22B.
What Is the Corcept (CORT) Share Price Target?
The average 12-month share price target for Corcept is 141.00, with a high estimate of 165 and a low estimate of 50. 4 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +15.34% Upside potential.
What Is Corcept's Earnings Per Share (TTM)?
The Corcept EPS (TTM) is 0.45.
When Is the Next Corcept Earnings Date?
Corcept will release its next earnings report on 04-11-2026.
From a Technical Analysis Perspective, Is CORT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Corcept Trade On?
Corcept is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Corcept?
The stock symbol for Corcept is "CORT."
How Many Times Has Corcept Stock Split?
Corcept has split 0 times.
How Many Employees Does Corcept Have?
Corcept has 730 employees.
What Is the CORT Premarket Price?
CORT's last pre-market stock price is 121.80. The pre-market share volume is 290.00, and the stock has changed by 0.75, or 0.62%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.